Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma.
In recent years, the outcome of Burkitt leukemia/lymphoma (BL) has improved significantly. Central nervous system (CNS) involvement continues to be a poor prognostic indicator. High doses of intravenous polychemotherapy, intrathecal chemotherapy, and cranio-spinal radiation therapy are used by numerous groups. Majority of patients are cured after this strategy. The next challenge is to decrease toxicities of treatment, including long-term toxicities secondary to cranio-spinal radiation therapy observed in these cured patients. Liposomal cytarabine could be a good alternative to cranio-spinal radiation therapy as already reported in acute lymphoblastic leukemia. We report here eleven patients treated in our center for BL, with liposomal cytarabine instead of cranio-spinal radiation therapy as prophylactic or curative treatment for CNS involvement. Treatment was safe with no short-term grade >3 adverse events. Moreover, no long-term side effects and no impact on outcome were observed. We conclude that LC could be a good option to decrease short/long-term side effects of cranio-spinal radiation therapy in BL and could be evaluated in a future clinical trial.
Adult Hematology Department, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Amandine
A
Segot
Adult Hematology Department, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.|EA3518, Institut Universitaire d'Hématologie, Université Paris 7, Paris, France.
Emmanuel
E
Raffoux
Adult Hematology Department, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.|EA3518, Institut Universitaire d'Hématologie, Université Paris 7, Paris, France.
Etienne
E
Lengline
Onco-Hematology Department, Saint Louis Hospital, Paris, France.
Catherine
C
Thieblemont
Adult Hematology Department, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.|EA3518, Institut Universitaire d'Hématologie, Université Paris 7, Paris, France.
Hervé
H
Dombret
EA3518, Institut Universitaire d'Hématologie, Université Paris 7, Paris, France.|Adolescents and Young Adult Unit, Saint Louis Hospital, Hematology, Paris, France.
Nicolas
N
Boissel
Adult Hematology Department, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France. cluzeau.thomas@gmail.com.|EA3518, Institut Universitaire d'Hématologie, Université Paris 7, Paris, France. cluzeau.thomas@gmail.com.|INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Nice, France. cluzeau.thomas@gmail.com.
Thomas
T
Cluzeau
D000293:Adolescent; D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000517:prevention & control* / Q000532:radiotherapy / Q000556:secondary; D018890:Chemoprevention / Q000009:adverse effects / Q000379:methods; D016371:Cranial Irradiation; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055815:Young Adult
D000964:Antimetabolites, Antineoplastic; D008081:Liposomes; D003561:Cytarabine
Burkitt leukemia/lymphoma; CNS involvement; Lyposomal cytarabine; Radiotherapy